The toxin producing bacterium Clostridium difficile causes an estimated 1,000,000 to 3,000,000 cases of diarrhea and colitis in the United States each year at an annual cost of $1.1 Billion dollars for nosocomial infections alone. Most cases are associated with the administration of broad-spectrum antibiotics. It has been assumed that the administration of antibiotics causes changes in the normal gastrointestinal microbiota. These changes allow overgrowth of C. difficile, which has either been present in low numbers in the gastrointestinal tract before the administration of antibiotics, or is acquired from the environment during antibiotic administration. Furthermore, it is likely that C. difficile spores and not the vegetative bacilli are the direct contagion analogous to other pathogenic Clostridia sp. Spores are hardy, not easily cleared from the body by natural means and are resistant to antibiotics. We theorize that the normal gastrointestinal microbiota interferes with gut colonization by C. difficile and may also regulate expression of toxin by the organism. Additionally, we hypothesize that the spore morphotype itself contributes heavily to not only the initial introduction of C. difficile to the host, but also to recurrent relapse and shedding/transmission. To address these hypotheses, three specific aims are proposed for this project. In the first aim, we will compare the fecal microbiota in asymptomatically colonized individuals and patients with initial or recurrent C. difficile infection of varied severity. We will determine if specific community structures correlate with susceptibility to disease and with clinical outcomes/severity.
The second aim will extend these observations in a murine model of C. difficile infection to define the microbiologic factors that contribute to colonization resistance against C. difficile. In the third aim the contribution of germination and sporulation to clinical disease and transmission will be determined. We will characterize clinical C. difficile isolates for sporulation/germination attributes and test naturally occurring variants and defined mutants in the murine C. difficile model.
These aims will provide important insight in the roles of microbial ecology and molecular bacterial pathogenesis in C. difficile infection.

Public Health Relevance

Treatment with antibiotics can lead to infection and disease with the bacterium Clostridium difficile. The proposed research will study the role ofthe existing gut bacteria and the ability ofthe pathogen to form spores in disease related to C. difficile infection. The overall goal is to increase our ability to come up with novel ways to prevent and treat this important human infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI090871-04
Application #
8508840
Study Section
Special Emphasis Panel (ZAI1-BLG-M)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$405,927
Indirect Cost
$144,881
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Seekatz, Anna M; Wolfrum, Emily; DeWald, Christopher M et al. (2018) Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease. Anaerobe :
Rao, Krishna; Higgins, Peter D R; Young, Vincent B (2018) An Observational Cohort Study of Clostridium difficile Ribotype 027 and Recurrent Infection. mSphere 3:
Seekatz, Anna M; Theriot, Casey M; Rao, Krishna et al. (2018) Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe :
Ulrich, Robert J; Santhosh, Kavitha; Mogle, Jill A et al. (2017) Is Clostridium difficile infection a risk factor for subsequent bloodstream infection? Anaerobe 48:27-33
Chen, Liang; Wilson, Justin E; Koenigsknecht, Mark J et al. (2017) NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat Immunol 18:541-551
Dahl, Jan-Ulrik; Gray, Michael J; Bazopoulou, Daphne et al. (2017) The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation. Nat Microbiol 2:16267
McDermott, Andrew J; Falkowski, Nicole R; McDonald, Roderick A et al. (2017) Role of interferon-? and inflammatory monocytes in driving colonic inflammation during acute Clostridium difficile infection in mice. Immunology 150:468-477
Young, V B (2016) Therapeutic manipulation of the microbiota: past, present, and considerations for the future. Clin Microbiol Infect 22:905-909
Stokely, Janelle N; Niendorf, Sandra; Taube, Stefan et al. (2016) Prevalence of human norovirus and Clostridium difficile coinfections in adult hospitalized patients. Clin Epidemiol 8:253-60
Rao, Krishna; Santhosh, Kavitha; Mogle, Jill A et al. (2016) Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults. Infect Dis (Lond) 48:663-9

Showing the most recent 10 out of 87 publications